Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
6,887,242
-
Total 13F shares
-
2,000,189
-
Share change
-
-82,856
-
Total reported value
-
$5,500,414
-
Price per share
-
$2.75
-
Number of holders
-
21
-
Value change
-
-$431,314
-
Number of buys
-
5
-
Number of sells
-
9
Institutional Holders of Aprea Therapeutics, Inc. - Common Stock (APRE) as of Q3 2024
As of 30 Sep 2024,
Aprea Therapeutics, Inc. - Common Stock (APRE) was held by
21 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,000,189 shares.
The largest 10 holders included
AIGH Capital Management LLC, Sio Capital Management, LLC, SPHERA FUNDS MANAGEMENT LTD., Nantahala Capital Management, LLC, VANGUARD GROUP INC, Stonepine Capital Management, LLC, DAFNA Capital Management LLC, Exome Asset Management LLC, GEODE CAPITAL MANAGEMENT, LLC, and MORGAN STANLEY.
This page lists
21
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.